מזומן למניה Cardio Diagnostics Holdings Inc. (CDIO)

Management at Cardio Diagnostics (CDIO) possesses a strong scientific background and is currently optimizing expenses amid capital shortages. The company's revenue is based on the sale of AI tests for detecting cardiac pathologies via blood analysis. Cash per share demonstrates genuine financial stability, where the value of 1.33 describes the current level. This enables the scaling of autonomous IT systems that automate epigenetic diagnostics.
פילוחי מדדים מקיפים ואנליטיקה עבור Cardio Diagnostics Holdings, Inc. (CDIO)

Cardio Diagnostics (CDIO) is transforming cardiology by identifying heart attack risks through epigenetic blood analysis. The trend in cash per share demonstrates the volume of liquid reserves available for each unit of equity. This indicator measures financial stability by excluding market volatility from the valuation. A high level of funds minimizes the probability of bankruptcy, creating a defensive layer for innovation. However, excessive liquidity may constrain the asset's overall return.